[go: up one dir, main page]

FI20011478L - Farmaseuttinen koostumus - Google Patents

Farmaseuttinen koostumus Download PDF

Info

Publication number
FI20011478L
FI20011478L FI20011478A FI20011478A FI20011478L FI 20011478 L FI20011478 L FI 20011478L FI 20011478 A FI20011478 A FI 20011478A FI 20011478 A FI20011478 A FI 20011478A FI 20011478 L FI20011478 L FI 20011478L
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
FI20011478A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011478A0 (fi
FI117667B (fi
Inventor
Hermann Sailer
Franz Weber
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Priority to FI20011478A priority Critical patent/FI117667B/fi
Publication of FI20011478A0 publication Critical patent/FI20011478A0/fi
Priority to CA002387981A priority patent/CA2387981A1/en
Priority to US10/189,302 priority patent/US7041645B2/en
Priority to EP02396115A priority patent/EP1273303A1/en
Priority to MXPA02006679A priority patent/MXPA02006679A/es
Publication of FI20011478L publication Critical patent/FI20011478L/fi
Priority to US11/346,673 priority patent/US7358227B2/en
Application granted granted Critical
Publication of FI117667B publication Critical patent/FI117667B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20011478A 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä FI117667B (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA002387981A CA2387981A1 (en) 2001-07-05 2002-06-25 Pharmaceutical composition
US10/189,302 US7041645B2 (en) 2001-07-05 2002-07-02 Methods of inhibiting or inducing bone formation
EP02396115A EP1273303A1 (en) 2001-07-05 2002-07-04 Pharmaceutical composition comprising a mixture of at least two rBMPs and the use thereof in the treatment of orthopaedic and dental patients
MXPA02006679A MXPA02006679A (es) 2001-07-05 2002-07-04 Composicion farmaceutica.
US11/346,673 US7358227B2 (en) 2001-07-05 2006-02-03 Pharmaceutical compositions comprising bone morphogenetic protein monomers for inhibiting bone formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
FI20011478 2001-07-05

Publications (3)

Publication Number Publication Date
FI20011478A0 FI20011478A0 (fi) 2001-07-05
FI20011478L true FI20011478L (fi) 2003-01-06
FI117667B FI117667B (fi) 2007-01-15

Family

ID=8561603

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä

Country Status (5)

Country Link
US (2) US7041645B2 (fi)
EP (1) EP1273303A1 (fi)
CA (1) CA2387981A1 (fi)
FI (1) FI117667B (fi)
MX (1) MXPA02006679A (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298140A2 (en) 2001-08-24 2003-04-02 University Of Zurich Mutants of bone morphogenetic proteins (BMP)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
CN101652387A (zh) 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN104520321A (zh) * 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
EP3004153B1 (en) * 2013-06-04 2019-10-30 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
EP3027642B1 (en) * 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
KR102398246B1 (ko) 2014-06-30 2022-05-17 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
MX370115B (es) * 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
MY186702A (en) * 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
ITMI20150558A1 (it) * 2015-04-16 2016-10-16 Univ Politecnica Delle Marche Irisina per la cura e la prevenzione dell'osteoporosi
US10517926B2 (en) * 2015-05-20 2019-12-31 Osaka University Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
US11571462B2 (en) * 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
EP3666282A1 (en) * 2015-06-03 2020-06-17 The Medical College of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
CA2998390A1 (en) * 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
AU2016361461B2 (en) * 2015-11-26 2020-10-22 Hudson Institute of Medical Research Inhibin analogs
US20190000923A1 (en) * 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3439686A4 (en) * 2016-04-06 2019-10-09 Acceleron Pharma Inc. BMPRII POLYPEPTIDES AND USES THEREOF
DK3496739T3 (da) * 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
US11285191B2 (en) * 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
WO2018187209A1 (en) * 2017-04-03 2018-10-11 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
EP3512874A2 (en) * 2017-11-30 2019-07-24 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
MX2020014296A (es) * 2018-06-22 2021-08-05 Cugene Inc Variantes de interleucina-2 y sus métodos de uso.
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020151631A1 (zh) * 2019-01-27 2020-07-30 中国医药大学 一种类风湿性关节炎自体抗体结合的肽及其应用
CA3137512A1 (en) * 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
EP3983433A4 (en) * 2019-06-14 2023-08-09 Cugene Inc. NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT
US11851490B2 (en) * 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
WO2021044361A1 (en) * 2019-09-06 2021-03-11 Novartis Ag Therapeutic fusion proteins
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CN115348967A (zh) * 2019-12-03 2022-11-15 洪明奇 寡胜肽，其检测套组，其医药组合物与医药组合物的用途
WO2021123173A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
AU2021210773B2 (en) * 2020-01-23 2024-11-07 Genexine, Inc. Fusion protein comprising pd-l1 protein and use thereof
CA3185618A1 (en) * 2020-06-04 2021-12-09 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Modified semaphorin 3a, compositions comprising the same and uses thereof
JP2023544959A (ja) * 2020-09-24 2023-10-26 グブラ エー／エス 改善されたアミリン受容体（ｈＡＭＹ３Ｒ）効力を有するｈＡＭ１５－５２類似体
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
KR20250152662A (ko) * 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
JP2024519629A (ja) * 2021-05-17 2024-05-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生性眼疾患の治療のための長期の高用量ｖｅｇｆアンタゴニストレジメン
JP2024522069A (ja) 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． Ｉｌ－２１ポリペプチド及び標的化コンストラクト

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
CA2071912C (en) 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US6180606B1 (en) 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
AU3269399A (en) 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
WO2000064460A2 (en) 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298140A2 (en) 2001-08-24 2003-04-02 University Of Zurich Mutants of bone morphogenetic proteins (BMP)

Also Published As

Publication number Publication date
FI20011478A0 (fi) 2001-07-05
FI117667B (fi) 2007-01-15
CA2387981A1 (en) 2003-01-05
EP1273303A1 (en) 2003-01-08
MXPA02006679A (es) 2005-12-19
US7041645B2 (en) 2006-05-09
US7358227B2 (en) 2008-04-15
US20060147534A1 (en) 2006-07-06
US20030045474A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
FI20011478L (fi) Farmaseuttinen koostumus
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
DK1524266T3 (da) Farmaceutisk sammensætning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20033556L (no) Farmasöytiske formuleringer
NO20033384L (no) Farmasoytisk formulering
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1395242T3 (da) Flydende farmaceutisk sammensætning
BR0210619A (pt) composição
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
FI20022128L (fi) Farmaseuttinen koostumus
NO20026123L (no) Farmasöytiske sammensetninger
NO20031095L (no) Farmasoytiske sammensetninger
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
ITTO20020745A0 (it) Composizione
EP1413314A4 (en) MEDICAL COMPOSITIONS
EE200200689A (et) Ravimkoostised
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
NO20041236L (no) Farmasoytisk formulering

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117667

Country of ref document: FI